GC Therapeutics
Parastoo Khoshakhlagh, Ph.D. currently serves as CEO & Co-Founder at GC Therapeutics since April 2019. Additionally, Parastoo holds the position of Member of Board Of Directors & Co-Founder, as well as CSO and Co-Founder at Tympanogen since January 2014. Parastoo has a background as a Postdoctoral Research Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School and at Harvard-MIT Health Sciences and Technology. Parastoo also completed a Mini-MBA course at Harvard Business School in 2015. Parastoo completed their Doctor of Philosophy degree in Biomedical Engineering/Neural Engineering from Tulane University.
GC Therapeutics
1 followers
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.